Carl U M, Bahnsen J, Edel B, Chandra A
Klinik für Strahlentherapie und Radiologische Onkologie, Universität Düsseldorf.
Strahlenther Onkol. 1995 Jun;171(6):322-5.
The incidence of endometrial cancer has increased considerably within the last decades. Due to early symptoms more than 88% of all patients present initially with FIGO stage I or II disease.
One hundred and forty-four patients out of 192 patients with stage I endometrial cancers received surgical treatment alone. Like the remaining 48 patients 39 out of 65 patients with stage II tumors received adjuvant radiation therapy with 50 Gy to the true pelvis.
Independent on the chosen treatment results in stage I were influenced by the depth of myometrial invasion (p = 0.023). With a crude 5-year survival rate of 88% patients with less than 33% reached life expectation of matched healthy women. With deeper infiltration crude survival rates were as low as 77%. In stage II tumors 5-year crude survival was elevated 60 to 80% independent on the depth of myometrial infiltration by adjuvant radiation therapy (p = 0.11).
Despite its potential curability and the general knowledge that the prognosis of endometrial carcinomas is governed by a number of factors there are no generally accepted standard treatment modalities available Thus there is great demand for randomized clinical trials.
在过去几十年中，子宫内膜癌的发病率显著上升。由于早期症状，超过88%的患者初诊时为国际妇产科联盟（FIGO）I期或II期疾病。
192例I期子宫内膜癌患者中，144例仅接受了手术治疗。其余48例患者中，65例II期肿瘤患者中有39例接受了对真骨盆进行50 Gy的辅助放疗。
I期患者的治疗结果不受所选治疗方式影响，而是受肌层浸润深度影响（p = 0.023）。肌层浸润少于33%的患者，其粗略的5年生存率为88%，达到了匹配健康女性的预期寿命。浸润越深，粗略生存率低至77%。在II期肿瘤中，辅助放疗使5年粗略生存率提高到60%至80%，不受肌层浸润深度影响（p = 0.11）。
尽管子宫内膜癌具有潜在可治愈性，且人们普遍知道其预后受多种因素影响，但目前尚无普遍接受的标准治疗模式。因此，对随机临床试验有很大需求。
